High Vista Strategies LLC Protagonist Therapeutics, Inc Transaction History

High Vista Strategies LLC

$241 Million
Q2 2025

A detailed history of High Vista Strategies LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, High Vista Strategies LLC holds 57,851 shares of PTGX stock, worth $4.49 Million. This represents 1.33% of its overall portfolio holdings.

Number of Shares

57,851

Previous 78,452 26.26%

Holding current value

$4.49 Million

Previous $3.79 Million 15.71%

% of portfolio

1.33%

Previous 1.65%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$40.89 - $56.37 $842,374 - $1.16 Million	-20,601 Reduced 26.26%	57,851 $3.2 Million
Q1 2025 May 15, 2025	BUY	$35.09 - $59.76 $559,124 - $952,215	15,934 Added 25.49%	78,452 $3.79 Million
Q4 2024 Feb 14, 2025	SELL	$38.51 - $48.43 $1.04 Million - $1.31 Million	-26,990 Reduced 30.15%	62,518 $2.41 Million
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $2.3 Million - $3.23 Million	68,279 Added 321.63%	89,508 $4.02 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $155,362 - $229,229	-7,130 Reduced 25.14%	21,229 $614,000
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $398,443 - $664,734	28,359 New	28,359 $650,000
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $525,805 - $856,695	29,179 New	29,179 $805,000
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $321,837 - $1.16 Million	-45,586 Reduced 49.53%	46,459 $367,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.42 Million - $2.2 Million	61,046 Added 196.93%	92,045 $2.18 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $47,389 - $99,724	2,688 Added 9.49%	30,999 $1.06 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $31,831 - $122,138	2,458 Added 9.51%	28,311 $501,000
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $661,061 - $1.16 Million	25,853 New	25,853 $1.16 Million

Others Institutions Holding PTGX

# of Institutions

297

Shares Held

67.4M

Call Options Held

290K

Put Options Held

318K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $3.81B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.

Account

High Vista Strategies LLC Protagonist Therapeutics, Inc Transaction History